Clostridium Difficile Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Monoclonal Antibodies in Clostridium Difficile Infection
Condition: Clostridium Infection Intervention: Other: Collection of peripheral blood mononuclear cells Sponsors: Assistance Publique - Hôpitaux de Paris; Institut Pasteur Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 6, 2021 Category: Research Source Type: clinical trials

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ( “MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial
This study will use a multicentre, parallel group open-label non-inferiority trial design comparing ceftolozane-tazobactam and meropenem in adult patients with bloodstream infection caused by ESBL or AmpC-producing Enterobacterales. Trial recruitment will occur in up to 40 sites in six countries (Australia, Singapore, Italy, Spain, Saudi Arabia and Lebanon). The sample size is determined by a predefined quantity of ceftolozane-tazobactam to be supplied by Merck, Sharpe and Dohme (MSD). We anticipate that a trial with 600 patients contributing to the primary outcome analysis would have 80% power to declare non-inferiority w...
Source: Trials - April 22, 2021 Category: Research Source Type: clinical trials

The A2B trial , antibiotic prophylaxis for excision-graft surgery in burn patients: a multicenter randomized double-blind study
The objective of antibiotic prophylaxis is to reduce the risk of postoperative local and systemic infections. Burn surgery is associated with a high incidence of bacteremia, postoperative infections, and sepsis. However, antibiotic prophylaxis exposes patients to the risk of selecting drug-resistant pathogens as well as to the adverse effects of antibiotics (i.e.,Clostridium difficile colitis). The lack of data precludes any strong international recommendations regarding perioperative prophylaxis using systemic antibiotics in this setting.The goal of this project is therefore to determine whether perioperative systemic ant...
Source: Trials - November 25, 2020 Category: Research Source Type: clinical trials

Acurx Announces Positive Phase 2A Clinical Trial Results for Ibezapolstat in C. difficile Infection at Prominent International Conference
WHITE PLAINS, N.Y., Nov. 19, 2020 /PRNewswire/ -- Acurx Pharmaceuticals, LLC ( " Acurx " or the " Company " ), a privately held, clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 19, 2020 Category: Pharmaceuticals Source Type: clinical trials

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).
Conditions: Inflammatory Bowel Diseases; Ulcerative Colitis; Crohn Disease; C. Diff. Infections Intervention: Biological: Bezlotoxumab Sponsors: David Binion, MD; Merck Sharp & Dohme Corp. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 13, 2020 Category: Research Source Type: clinical trials